GlassScriptPhysician profile
Kevin Windsor
NPI 1801828405
$12,767.21
in general payments reported to CMS, 2019-2025
62 companies · $43.95 in 2025
The $43.95 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,821 · 2020: $5,709 · 2021: $2,583 · 2022: $1,558 · 2023: $51.60 · 2025: $43.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,190.54 | 2019-2022 | |
| Celgene Corporation | $1,122.08 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $1,043.48 | 2019-2021 | |
| Amgen INC. | $1,018.84 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $643.05 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $566.77 | 2019-2025 | |
| Seagen INC. | $465.08 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $439.53 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $436.79 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $428.32 | 2019-2022 | |
| Janssen Biotech, INC. | $387.71 | 2019-2022 | |
| Pfizer INC. | $276.65 | 2019-2022 | |
| Eisai INC. | $269.85 | 2019-2022 | |
| Incyte Corporation | $240.07 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $236.42 | 2019-2022 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Windsor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.